Pilot study of bone marrow-derived mesenchymal stem cells for the treatment of refractory hemorrhagic cystitis occurring after hematopoietic stem cell transplantation

The Catholic University of Korea, Seoul St. Mary's Hospital0 个研究点目标入组 3 人开始时间: 待定最近更新: 2021年1月6日

试验速览

暂无简介。

•1) Confirmed hemorrhagic cystitis patient occurring after allogeneic or autologous hematopoietic stem cell transplantation
•2) Patients with ECOG performance status rating of 0, 1, or 2
•3) Patients who are considered to be able to survive for 3 months or more
•4) Patients without evidence of acute infectious disease
•5) Patients who have no evidence of accompanying tumor

•1) Pregnant, lactating women or women who have the possibiity of being pregnant or who have not taken adequate contraceptive
•2) Patients with active infection or fever with unknown etiology or ongoing bacterial or fungal infection
•3) ECOG performance status of 3 or 4
•4) Patients with previously confirmed HIV infection, uncontrolled hypertension (diastolic blood pressure > 115mmg Hg), unstable angina, congestive heart failure (NY class II or higher), poorly controlled severe diabetes, coronary angioplasty within 6 months, Patients with acute myocardial infarction or non-malignant disease including uncontrolled atrial or ventricular arrhythmia within the last 6 months
•5) Patients with mental illnesses,drug addiction, etc. who are judged to have an influence on the outcome of the study
•6) Patients participating in other clinical trials (but, subject to the clinical judgment of the investigator)
•7) Patients who are judged to be inadequate due to the judgment of the person in charge of clinical trial (principal investigator)
•8) Patients with other serious medical conditions that may reduce compliance with clinical trials

发起方

The Catholic University of Korea, Seoul St. Mary's Hospital